OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

Director received an award of 957K OVID derivative securities | OQRO

Home
Insider trades
Ovid Therapeutics
Director received an award of 957K OVID derivative securities

Insider trades

Insider trade

Director received an award of 957K OVID derivative securities

Traded Feb 26, 2026 · Filed Mar 2, 2026

OVIOvid TherapeuticsOVID

957K
Derivative units

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Feb 26, 2026
Reporting period: Not applicable
Filed with the SEC: Mar 2, 2026

DirectorGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001256153-26-000002
Filed / recorded

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Mar 2, 2026, 9:30 PM UTC

Added to OQRO

Oct 7, 2026, 5:52 AM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

Ovid Therapeutics Inc.

Issuer CIK

1636651

Ticker

OVID

Reporting person

Jeremy M Levin

Relationship

Director

Security

Employee Stock Option (Right to Buy)

Table

Derivative (Table II)

Transaction date

Feb 26, 2026

Transaction code

Shares / units

957,000

Price per share

$0.00

Acquired / disposed

Acquired (A)

Shares owned after

957,000

Ownership form

Direct

Amendment

Footnotes from the filing

The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2026, subject to the Reporting Person's continued services through each such date.

Around the same time

Jeremy M LevinExecutive Chairman

Filed 7mo ago

47KShares · @ $1.40

Traded Mar 23 · filed 3 days later

Derivative exercise or conversion — not an open-market buy.

More Official record

Jeremy M LevinExecutive Chairman

Filed 7mo ago

47KDerivative units

Traded Mar 23 · filed 3 days later

Derivative exercise or conversion — not an open-market buy.

More Official record

Margaret A. Alexander (President and CEO) sold ~$17K of Ovid Therapeutics

Automatic saleFiled 7mo ago